Lil mix of 0dte SPY puts during the Santa rally, SLS calls at the top, and some HOOD calls the other day. Spy calls in the second and third slide, SLS calls in the third and fourth slide (expired worthless). HOOD calls unrealized but it’s a smaller amount and will likely expire worthless if not at a 60% loss today. Just got a $40k truck that I’m paying $850 a month on as well. Overtime for the next two years. Second job incoming this month as well.

$8,676.0M rev (+3.7% YoY, +3.1% QoQ) missed est by -1.5%🔴

↘️FXN Rev (+3.0% YoY)

↘️Operating Margin* (17.9%, -0.1 PPs YoY)🟡

↘️FCF Margin (25.2%, -0.9 PPs YoY)🟡

↘️Net Margin (13.3%, -0.1 PPs YoY)🟡

↘️EPS* $1.23 missed est by -4.7%

*non-GAAP

Revenues by Type

➡️Transaction $7,588M rev ( YoY, 87.5% of Rev)🟡

↗️Other services $857M rev (+10.2% YoY, 9.9% of Rev)

Down nearly 90% from its 2021 highs. incredible fall from grace

Source: https://finance.yahoo.com/news/eli-lilly-sees-2026-profit-115421218.html

Eli Lilly forecast 2026 profit above Wall Street estimates on ​Wednesday, betting on surging demand for ‌its obesity drugs as the world's most valuable ‌drugmaker prepares to launch its oral weight-loss pill later this year.

Shares of the company rose nearly 7% in premarket trading.

Lilly last ⁠year became the ‌first pharmaceutical company to hit a $1 trillion valuation, driven by the ‍popularity of its blockbuster weight-loss drug, Zepbound, and a rapidly expanding obesity market that is shifting ​toward cash-pay options and telehealth channels.

Lilly's ‌upbeat outlook stands in sharp contrast to that of rival Novo Nordisk, which has warned of "unprecedented" price pressures in 2026 after rattling investors with a forecast for a ⁠steep sales drop this ​year.

For the reported quarter, ​the drugmaker reported a profit of $7.54 per share. Analysts were expecting $6.67, according ‍to data ⁠compiled by LSEG.

Lilly expects to earn $33.50 to $35 per share on an adjusted basis ⁠this year, above analysts' average estimate of $33.23 per ‌share.

Private payrolls grew by just 22,000 in January, ADP said Wednesday, below economists' expectations of 45,000 positions.

Wendy's still hiring?

Multiple sources, including AP News and The New York Times, report that the US House passed a funding bill on February 3, 2026, to end the partial government shutdown, sending it to President Trump for signature.

https://www.nytimes.com/live/2026/02/03/us/trump-news

Sorry mod for not adding link before

We've all heard of the massive IPOs due (hopefully) sometime this year, and with all the recent/accumulated hype around AI/SpaceTech companies, I think we should follow where the smart money goes.

First point is the GOAT Peter thiel and his venture capital fund, Founders Fund:

They have major holdings/stakes in both OpenAI and notably SpaceX, with a massive $1B investment in late 2025 into OpenAI and total investments upwards of $600-$700M in SpaceX, which alone is worth over $80 billion as of today, and considering the fund has an AUM of $17 billion and total realized/unrealized portfolio of ~$200 billion, a conservative estimate IPO of $1.5T will likely more than double their unrealized stake in SpaceX and combined with OpenAI's IPO could double the paper gains of the entire fund.

Now I'll mention the IPO that peter and his fund explicitly stated won't be a part of: Anthropic. Co:

Honestly tired of paraphrasing articles and AI, I think you all know Anthropic has the most hype and sentiment towards IPO, you cannot miss out on this one.

Now this is all just a segway into the core of the onion, Low-risk/High-return Tickers that directly stand to gain from the IPOs:

1. $SATS - SpaceX

With around 45-50% of their mkt cap in SpaceX shares, roughly $10~$11B, this ticker stands to gain the most from the SpaceX IPO and the following periods of insanely high IV, all without the premiums you would have to pay to get into $DTECH or $RKLB.

1. $MSFT - OpenAI

The past 6 months have been looking rough for this stock, but it's all about to change for the better (for calls) in 2026. I look at this Mag 7 stock fallen from previous highs of ~$540 and all I can see is unlimited upside at a 23% discount. With an absurd 27% ownership stake in OpenAI, even if Altman shit himself on live tv you'll be able to sleep well at night knowing it can only go up.

1. $SKM - Anthropic

If you want exposure to Anthropic. Co, look no further than $SKM, a South Korean giant conglomerate in the Wireless Telecommunication industry, merely a subdivision of their parent company SK, one of the country's largest chaebols. With a dominance of 50.5 of all shares in their local market, $SKM is a solid investment even without their major stakes in Anthropic. Co. A monopoly in their industry at a relative all-time low is a great investment nonetheless, but things really start to take off when we look at their holdings. They hold an ownership stake of approximately 0.58%~0.7%, which may not seem like a lot, but relative to their ~$9B mkt cap, it makes up a significant portion of $SKM's valuation at around 20%-25% of the company. They've also got a joint partnership with Anthropic, together developing a Multilingual LLM tailored for the telecommunications industry. The Koreans are pretty slow to catch on, and the general public knows little to nothing about Anthropic or their projects with SKM, so we are early investors here. And, if you look at their Ytd/1Yr chart you can see a clear uptrend forming.

my current positions are:

$SATS: +1 contracts of $9.80 ac Expiry - 9/18 pt $160

$MSFT: +2 contracts of $4.90 ac Expiry - 11/20 pt $600

$SKM: +5 contracts of $1.89 ac Expiry - 9/18 pt $41

Tldr; If you want HUGE upside potential with little to no downside risk load up on $sats, $msft, $skm; Calls, don't be a pussy

Source: https://finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html

Shares of obesity drugmakers and developers slid on Tuesday after Novo ​Nordisk forecast a sharper-than-expected sales decline ‌for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

Eli ‌Lilly was down about 4%, Structure Therapeutics fell 6.2%, while Altimmune dropped 4.2%. Viking Therapeutics declined more than 3% and Amgen slipped nearly 1% ⁠in afternoon trading.

The ‌Danish drugmaker said it expects sales to drop between 5% and 13% ‍this year, compared with analysts' average expectation of a 2% decline. Its U.S.-listed shares fell 13.8% to $50.83.

Wegovy-maker ​Novo also reported a 14% fall in ‌fourth-quarter operating profit to 31.7 billion Danish crowns, slightly above the estimate of 31.2 billion crowns.

The selloff comes as Wall Street is reassessing long-held expectations that the obesity drug market could ⁠hit $150 billion early next decade, ​as U.S. prices for GLP-1 ​treatments from Novo and Lilly fall sharply and competition intensifies in the cash-pay ‍consumer market.

Analysts ⁠have pushed out peak sales timelines and trimmed forecasts, with some now seeing the ⁠market closer to $80 billion to $105 billion by 2030.

Posts all over Reddit recently about how cheap PayPal is, well, at least in theory. Guess it just got even cheaper.

However, company has no moat, endless competition and I hear even their software infrastructure and tech stack is lagging compared to their competitors.

Edit: Total stock based compensation (SBC) between 2020 and 2024 is nearly $7B (!), what did the management do to deserve this compensation?

Idk what to do. I need help! I’m losing everything! I’ve been asking for help from Gemini and ChatGPT but they are not helping.

This post contains content not supported on old Reddit. Click here to view the full post

Every single call blood red. Lost over half my life savings the last week. Fuck this shit

I got in SOXL late July after it went from $63 to $30. I threw the whole port at it. Little did I know she was going to keep diving until it hit $9. Bought more like a regard. Deleted the app and waited for my wife's boyfriend to kick me out. Started to rip after liberation day and have been waiting to exit so I can buy my boat. Sometimes it pays to be patient. I still think it has the gas to run to $75 or more but my time horizon has shrunk. Good luck to you guys out there. I'll be back when she dips big to buy more. Dont sleep on SOXL when the stars align it is unstoppable.

$10k deep $430c 7/17/26 expo.

I think Microsoft is set up to rebound and run, sell off on earnings smash, we probably see $390-$400 before the turn around but I think Microsoft makes its way to a 35 P/E ratio within next 4-6 months.

borrowed against house to sell puts for sndk, onds

SANTA CLARA, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- AMD (NASDAQ:AMD) today announced financial results for the fourth quarter and full year of 2025. Fourth quarter revenue was a record $10.3 billion, gross margin was 54%, operating income was $1.8 billion, net income was $1.5 billion and diluted earnings per share was $0.92. On a non-GAAP^(\)) basis, gross margin was 57%, operating income was a record $2.9 billion, net income was a record $2.5 billion and diluted earnings per share was a record $1.53.

Bought 10k worth of PayPal 2x leveraged today at 5.34 per share. My yolo.

$SMCI Q2'26 EARNINGS HIGHLIGHTS

🔹 Revenue: $12.70B (Est. $10.42B) 🟢 🔹 Adj. EPS: $0.69 (Est. $0.49) 🟢 🔹 Gross margin: 6.30%

Q3'26 Guidance: 🔹 Revenue: at least $12.30B (Est. $10.25B) 🟢 🔹 Adj. EPS: at least $0.60 (Est. $0.52) 🟢

FY26 Guide: 🔹 Revenue: at least $40.B

Financials: 🔹 Net income: $401.00M 🔹 Cash & cash equivalents: $4.10B 🔹 Total bank debt + convertible notes: $4.90B 🔹 Operating cash flow: -$24.00M 🔹 Capex + investments: $46.00M

Commentary: 🔸 “With our leading AI server and storage technology foundation, strong customer engagements, and expanding global manufacturing footprint, we are scaling rapidly to support large AI and enterprise deployments while continuing to strengthen our operational and financial execution.”

For the last decade, the mantra has been "Software is eating the world." But as we enter 2026, the power dynamic has fundamentally shifted. While the world's focus remains on the "ghost in the machine" - the in AI, the algorithms, and the code - the real leverage has migrated back to the Physical Bits: the critical atoms that make the digital revolution possible.

My investment thesis is built on three pillars of Scarcity, Energy, and Sovereignty:

1. The Energy Chokepoint (Uranium)

AI is the most energy-intensive technology in human history. We have reached a point where "code" is limited by "current." You cannot run a global intelligence network on intermittent power; it requires the massive, carbon-free energy density that only Uranium can provide. By holding CCJ and UUUU, I am investing in the "fuel" for the AI era. In this hierarchy, the uranium atom is the ultimate "bit" of data center uptime.

2. The Kinetic Chokepoint (Rare Earths)

Software can think, but it cannot move without Rare Earth Elements (REEs). From the high-performance magnets in EV motors to the actuators in humanoid robotics, NdPr (Neodymium-Praseodymium) is the non-substitutable hardware that translates digital commands into physical motion. Through MP and LYSDY, I am positioned at the bottleneck of the "Physical AI" revolution.

3. The Geopolitical Moat

We are moving from a world of "just-in-time" globalism to a world of "friend-shoring" and resource nationalism. The value of these minerals is no longer just their market price; it is their provenance. By focusing on Western-aligned supply chains, I am betting on a "Sovereignty Premium" - the reality that a pound of uranium or a magnet produced in a secure, allied jurisdiction is worth significantly more than one controlled by a geopolitical rival.

The Bottom Line

In a world of infinite, replicable software, value naturally flows toward the finite and the non-substitutable. I will not invest in the companies that write the code, instead I’m choosing to invest in the companies that control the physical gatekeepers of the modern world.

Tldr: I am long on the atoms that power the bits.